Unified Platforms Seen as Key to Manufacturing Quality
A platform-based approach to modernizing manufacturing technology is demonstrating measurable improvements in efficiency and quality. A case study of Carestream Health highlights how consolidating fragmented IT systems for quality and operations into a unified architecture improves regulatory readiness. For gene therapy CDMOs, this reinforces the strategy of integrating LIMS, MES, and electronic batch record systems to achieve real-time process visibility and control.
- Fragmented data systems are a primary source of data integrity deficiencies cited in FDA warning letters, with issues often related to regulations like 21 CFR Part 11 that mandate secure, time-stamped audit trails for all electronic records. Disconnected systems can lead to incomplete patient records, inconsistent manufacturing data, and siloed information that hampers real-time decision-making and regulatory compliance. - The "Pharma 4.0" initiative drives the integration of MES, LIMS, and EBRs as the data backbone for advanced technologies like AI, machine learning, and digital twins. This unified data environment is essential for developing predictive models for process optimization and enhancing real-time decision-making in bioprocess engineering. - For cell and gene therapies, which often involve complex and variable manufacturing processes, a lack of standardized data management tools can decrease efficiency, especially for autologous therapies where production volume directly increases data collection demands. Standardizing the most critical 20% of manufacturing steps can significantly streamline and improve the efficiency and quality of the overall process. - Digital twin technology, which creates a virtual simulation of a bioprocess using real-time data, relies on an integrated data platform to function. In viral vector manufacturing, companies like Généthon and Thalès are collaborating to use AI and digital models to simulate bioprocessing steps to optimize yields. - Integrating MES and LIMS can accelerate batch release by up to 30-50% and reduce manual documentation errors by 70%, delivering significant annual savings for mid-to-large-scale operations. Case studies show that implementing EBR systems can lead to a 75% drop in data recording errors and faster batch reviews. - The growing adoption of digitalization is a key trend for CDMOs, who are moving from transactional relationships to strategic partnerships with pharma companies. Pharmaceutical companies are increasingly prioritizing CDMO partners with advanced digital capabilities, including AI-driven analytics and digital twin technology, to improve supply chain resilience and efficiency. - A significant barrier to creating unified data systems in cell and gene therapy is the lack of a standardized "language" for defining process steps, data elements, and parameters, which complicates comparisons across different facilities or products. Collaborative initiatives are needed to define shared data standards and secure methods for information exchange. - Data fragmentation from siloed legacy systems can cost a biopharma company an estimated $12.9 million per year due to process inefficiencies and inaccurate reporting. A unified data infrastructure is the foundation for applying AI to glean insights for omnichannel implementations and building a comprehensive data narrative.
